Colorado Blood Cancer Institute (CBCI) is an established research leader in communities throughout Colorado, Montana, Wyoming and New Mexico. It offers clinical trials through Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials. SCRI has contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today.
Our research program, SCRI at Colorado Blood Cancer Institute, provides access to the latest clinical trial options to people facing cancer. Through SCRI, CBCI is a part of an expansive research network aimed at advancing therapies for patients and providing innovative therapies in the community, where the majority of people seek cancer treatment.
If you have any questions regarding CBCI's clinical trials.
Explore clinical trials available at CBCI and across SCRI's network below.
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Amyloid
- Autoimmune Diseases
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myelomonocytic Leukemia (CMML)
- Hematopoietic Cell Transplantation
- Hematologic Refractory
- Lymphoma
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasms
- Multiple Myeloma
- Waldenstrom's Macroglobulinemia